XML 30 R19.htm IDEA: XBRL DOCUMENT
v3.25.1

Stock-Based Compensation | 3 Months Ended
--- | ---
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract] |
Equity-Based Compensation | The following table summarizes the number of shares of common stock authorized for issuance under the 2019 Plan, the number of stock-based awards granted (net of expired or cancelled awards) under the 2019 Plan, and the number of shares of common stock available for the grant of stock-based awards under the 2019 Plan:
Common stock authorized(1) | 19,000
Stock-based awards, including restricted stock and stock options granted, net of expired or cancelled awards | (10,455)
Common stock available for grant of stock-based awards as of March 31, 2025 | 8,545
(1) On May 22, 2024, the stockholders of the Company approved amendments to the Steven Madden, Ltd. 2019 Plan to, among other things, increase the number of shares of Company common stock available for issuance under the 2019 Plan. As amended, the 2019 Plan provides that up to a total of 19,000 shares of the Company’s common stock may be issued thereunder. In addition, vested and unvested options to purchase 31 shares of common stock and 133 shares of unvested restricted stock awarded under the 2006 Plan were outstanding as of March 31, 2025. Total equity-based compensation for the three months ended March 31, 2025 and 2024 is as follows:
|  | Three Months Ended March 31,
|  | 2025 |  | 2024
Restricted stock |  | $ | 5,693 |  |  | $ | 5,192 |
Stock options |  | 658 |  |  | 546 |
Performance-based awards |  | 804 |  |  | — |
Total |  | $ | 7,155 |  |  | $ | 5,738 |
Equity-based compensation is included in operating expenses in the Company’s Condensed Consolidated Statements of Income. Stock Options Cash proceeds and intrinsic values related to total stock options exercised during the three months ended March 31, 2025 and 2024 are as follows:
|  | Three Months Ended March 31,
|  | 2025 |  | 2024
Proceeds from stock options exercised |  | $ | — |  |  | $ | 222 |
Intrinsic value of stock options exercised |  | $ | — |  |  | $ | 142 |
During the three months ended March 31, 2025, no options to purchase shares vested. During the three months ended March 31, 2024, options to purchase 73 shares vested with a weighted average exercise price of $32.58. As of March 31, 2025, there were unvested options relating to 99 shares of common stock outstanding with a total of $761 of unrecognized compensation cost and an average vesting period of 1.3 years. The Company uses the Black-Scholes-Merton option-pricing model to estimate the fair value of options granted, which requires several assumptions. The expected term of the options represents the estimated period of time until exercise and is based on the historical experience of similar awards. Expected volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The dividend yield is based on the Company's annualized dividend per share amount divided by the Company's stock price. The following weighted average assumptions were used for stock options granted during the three months ended March 31, 2025 and 2024:
|  | Three Months Ended March 31,
|  | 2025 |  | 2024
Volatility |  | 33.6% |  | 47.4%
Risk free interest rate |  | 4.3% |  | 4.0%
Expected life in years |  | 4.0 |  | 4.0
Dividend yield |  | 2.0% |  | 2.0%
Weighted average fair value |  | $11.65 |  | $15.69
Activity relating to stock options granted under the Company’s plans during the three months ended March 31, 2025 was as follows:
|  | Number of Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term |  | Aggregate Intrinsic Value
Outstanding at January 1, 2025 |  | 1,268 |  | $ | 36.82 |  |  |  |  |
Granted |  | 9 |  | 42.52 |  |  |  |  |
Outstanding at March 31, 2025 |  | 1,277 |  | $ | 36.86 |  |  | 2.5 years |  | $ | — |
Exercisable at March 31, 2025 |  | 1,178 |  | $ | 36.50 |  |  | 2.3 years |  | $ | — |
Activity relating to stock options granted under the Company’s plans during the three months ended March 31, 2024 was as follows:
|  | Number of Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term |  | Aggregate Intrinsic Value
Outstanding at January 1, 2024 |  | 1,119 |  | $ | 35.62 |  |  |  |  |
Granted |  | 8 |  | 42.00 |  |  |  |  |
Exercised |  | (9) |  | 26.10 |  |  |  |  |
Outstanding at March 31, 2024 |  | 1,118 |  | $ | 35.73 |  |  | 3.0 years |  | $ | 7,776 |
Exercisable at March 31, 2024 |  | 1,000 |  | $ | 35.75 |  |  | 2.8 years |  | $ | 6,943 |
Restricted Stock The following table summarizes restricted stock activity during the three months ended March 31, 2025 and 2024:
|  | 2025 |  | 2024
|  | Number of Shares |  | Weighted Average Fair Value at Grant Date |  | Number of Shares |  | Weighted Average Fair Value at Grant Date
Outstanding at January 1, |  | 1,543 |  | $ | 38.89 |  |  | 1,278 |  | $ | 35.44 |
Granted |  | 622 |  | 34.69 |  |  | 534 |  | 42.14 |
Vested |  | (419) |  | 39.28 |  |  | (237) |  | 34.90 |
Forfeited |  | (3) |  | 42.30 |  |  | (18) |  | 36.76 |
Outstanding at March 31, |  | 1,743 |  | $ | 37.29 |  |  | 1,557 |  | $ | 37.78 |
As of March 31, 2025, the Company had $56,930 of total unrecognized compensation cost related to restricted stock awards granted under the 2019 Plan and the 2006 Plan. This cost is expected to be recognized over a weighted average period of 3.6 years. The Company determines the fair value of its restricted stock awards based on the market price of its common stock on the date of grant. The fair values of the restricted stock that vested during the three months ended March 31, 2025 and 2024 were $16,466 and $8,268, respectively. Performance-Based Awards The Company issues performance-based awards to certain employees, the vesting of which is subject to the employee’s continuing employment and the Company's achievement of certain performance goals. In the first quarters of 2025 and 2024, the Company issued 150 and 86, performance shares (at target), respectively, with a weighted average grant date fair value of $26.05 and $41.63, respectively, that are eligible to be earned over a three-year performance period from January 1, 2025 through December 31, 2027 and January 1, 2024 through December 31, 2026, respectively. During the three months ended March 31, 2025, the Company estimated that the probable outcome of the performance conditions, based on performance through such date, was that the performance shares will be earned at 185% of the target level. The corresponding expense for the year ended March 31, 2025 is reflected in the stock-based compensation under performance-based awards. As of March 31, 2025, $10,717 of total unrecognized compensation cost related to non-vested share awards is expected to be recognized using the accelerated attribution method over a weighted-average period of 2.4 years. No performance-based shares vested in the three months ended March 31, 2025 and 2024.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration